Connection

RAJENDER APARASU to Middle Aged

This is a "connection" page, showing publications RAJENDER APARASU has written about Middle Aged.
Connection Strength

1.021
  1. Marginal health care expenditures for melanoma care in the United States. J Manag Care Spec Pharm. 2024 Dec; 30(12):1364-1374.
    View in: PubMed
    Score: 0.059
  2. Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180.
    View in: PubMed
    Score: 0.059
  3. Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2025 Feb; 117(2):561-569.
    View in: PubMed
    Score: 0.059
  4. Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105896.
    View in: PubMed
    Score: 0.059
  5. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis. Mult Scler Relat Disord. 2024 May; 85:105539.
    View in: PubMed
    Score: 0.056
  6. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study. Clin Ther. 2023 09; 45(9):e177-e186.
    View in: PubMed
    Score: 0.054
  7. Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study. Clin Rheumatol. 2024 Jan; 43(1):103-116.
    View in: PubMed
    Score: 0.054
  8. Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data. Mult Scler Relat Disord. 2022 Oct; 66:104019.
    View in: PubMed
    Score: 0.050
  9. FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Mult Scler Relat Disord. 2022 Apr; 60:103703.
    View in: PubMed
    Score: 0.049
  10. Opioid Prescribing Among Outpatients with Rheumatoid Arthritis. Pain Med. 2021 10 08; 22(10):2224-2234.
    View in: PubMed
    Score: 0.048
  11. Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Mult Scler Relat Disord. 2020 Oct; 45:102334.
    View in: PubMed
    Score: 0.044
  12. Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749.
    View in: PubMed
    Score: 0.043
  13. Discharge medication complexity and 30-day heart failure readmissions. Res Social Adm Pharm. 2017 Jul - Aug; 13(4):857-863.
    View in: PubMed
    Score: 0.034
  14. Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder. Drugs Aging. 2016 10; 33(10):755-763.
    View in: PubMed
    Score: 0.034
  15. Quality of life of patients with Parkinson's disease and neurodegenerative dementia: A nationally representative study. Res Social Adm Pharm. 2016 Jul-Aug; 12(4):604-13.
    View in: PubMed
    Score: 0.031
  16. Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study. Am J Geriatr Pharmacother. 2012 Apr; 10(2):83-94.
    View in: PubMed
    Score: 0.024
  17. Drug use trends for arthritis and other rheumatic conditions and effect of patient's age on treatment choice. N C Med J. 2011 Nov-Dec; 72(6):432-8.
    View in: PubMed
    Score: 0.024
  18. Risk of serious cardiac events in older adults using antipsychotic agents. Am J Geriatr Pharmacother. 2011 Apr; 9(2):120-32.
    View in: PubMed
    Score: 0.023
  19. Concomitant antipsychotic prescribing in US outpatient settings. Res Social Adm Pharm. 2009 Sep; 5(3):234-41.
    View in: PubMed
    Score: 0.020
  20. Hypertension management in outpatient visits by diabetic patients. Res Social Adm Pharm. 2008 Sep; 4(3):284-91.
    View in: PubMed
    Score: 0.019
  21. Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004. Curr Med Res Opin. 2008 Mar; 24(3):709-16.
    View in: PubMed
    Score: 0.018
  22. Clinically important potential drug-drug interactions in outpatient settings. Res Social Adm Pharm. 2007 Dec; 3(4):426-37.
    View in: PubMed
    Score: 0.018
  23. Antipsychotic utilization and expenditure trends among elderly persons. Psychiatr Serv. 2007 Nov; 58(11):1400.
    View in: PubMed
    Score: 0.018
  24. Patterns of gabapentinoid use among long-term opioid users. Prev Med. 2024 Aug; 185:108046.
    View in: PubMed
    Score: 0.014
  25. Patients' willingness to pay for naloxone: A national cross-sectional survey of prescription opioid users with chronic pain in the United States. J Am Pharm Assoc (2003). 2024 May-Jun; 64(3):102062.
    View in: PubMed
    Score: 0.014
  26. Autonomous ambulatory care by nurse practitioners and physician assistants in office-based settings. J Allied Health. 2001; 30(3):153-9.
    View in: PubMed
    Score: 0.011
  27. Utilization of ambulatory care services caused by adverse effects of medications in the United States. Manag Care Interface. 2000 Apr; 13(4):70-5.
    View in: PubMed
    Score: 0.011
  28. Opioid-induced emesis among hospitalized nonsurgical patients: effect on pain and quality of life. J Pain Symptom Manage. 1999 Oct; 18(4):280-8.
    View in: PubMed
    Score: 0.010
  29. Drug-related-injury visits to hospital emergency departments. Am J Health Syst Pharm. 1998 Jun 01; 55(11):1158-61.
    View in: PubMed
    Score: 0.009
  30. Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiol Infect. 2018 07; 146(9):1101-1105.
    View in: PubMed
    Score: 0.009
  31. Louisiana hospital pharmacists' membership in ASHP. Am J Health Syst Pharm. 1996 Nov 15; 53(22):2737-9.
    View in: PubMed
    Score: 0.009
  32. Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension. J Alzheimers Dis. 2016; 49(2):423-32.
    View in: PubMed
    Score: 0.008
  33. Use of Statins and Risk of Dementia in Heart Failure: A Retrospective Cohort Study. Drugs Aging. 2015 Sep; 32(9):743-54.
    View in: PubMed
    Score: 0.008
  34. Application of the nonlinear Blinder-Oaxaca decomposition to study racial/ethnic disparities in antiobesity medication use in the United States. Res Social Adm Pharm. 2013 Jan-Feb; 9(1):13-26.
    View in: PubMed
    Score: 0.006
  35. Effect of certain angiotensin-converting enzyme inhibitors on mortality in heart failure: a multiple-propensity analysis. Res Social Adm Pharm. 2012 Mar-Apr; 8(2):145-56.
    View in: PubMed
    Score: 0.006
  36. The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psychiatr Serv. 2008 Oct; 59(10):1191-7.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.